Answers are grounded in this paper and cite their sources.
Purpose: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. Experimental Design: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. Results: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype–outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5–0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89–0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. Conclusions: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: